SAN DIEGO, Feb. 9, 2007 (PRIME NEWSWIRE) -- Optimer Pharmaceuticals, Inc. announced today the initial public offering of 7,000,000 shares of its common stock at a price of $7.00 per share. The common stock will be listed on the NASDAQ Global Market under the trading symbol "OPTR." A selling stockholder has granted the underwriters an option to purchase up to an additional 1,050,000 shares at the initial public offering price to cover over-allotments, if any.
Piper Jaffray & Co. and Jefferies & Company, Inc. are acting as joint book-running managers. JMP Securities LLC and Rodman & Renshaw, LLC are acting as co-managers for the offering.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from Piper Jaffray & Co., 800 Nicollet Mall, Minneapolis, Minnesota 55402 or by fax at (612) 303-1070, and from Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY 10022 or by fax at (212) 284-2208.
The Securities and Exchange Commission declared a registration statement relating to these securities effective on February 8, 2007. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Optimer Pharmaceuticals, Inc.
Optimer Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products for the treatment of serious infections. Optimer currently has two late-stage anti-infective product candidates. Difimicin (OPT-80) is an antibiotic currently in a Phase 2b/3 registration trial for the treatment of Clostridium difficile-associated diarrhea, the most common hospital-acquired diarrhea. Prulifloxacin (OPT-99) is an antibiotic currently in a Phase 3 trial for the treatment of travelers' diarrhea, a form of infectious diarrhea. The Company is developing additional product candidates using its proprietary technology, including its Optimer One-Pot Synthesis drug discovery platform.